BOCA RATON, Fla., Oct. 24 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) (the "Company") announced today that on
October 18, 2007, it commenced mailing its definitive proxy statement to
stockholders for approval of its proposed sale of its biologics strategic
business unit and certain corporate shared services assets to Biotest
Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG,
pursuant to an asset purchase agreement dated as of September 11, 2007. The
Company has scheduled a special meeting of stockholders for Thursday,
November 8, 2007 at 10:00 a.m. EST at the Bethesda Marriott, 5151 Pooks
Hill Road in Bethesda, Maryland, to consider and vote on the proposed asset
sale. Stockholders of record as of the close of business on October 10,
2007 will be entitled to vote at the special meeting.
The Company's Board of Directors has unanimously determined that the
proposed asset sale is in the best interests of the Company and recommends
that stockholders vote "FOR" the proposed sale.
Stockholders are encouraged to read the Company's definitive proxy
materials in their entirety as they provide, among other things, a detailed
discussion of the process that led to the proposed asset sale and reasons
behind the Board of Directors' unanimous recommendation. In addition, the
Company will be mailing stockholders a supplement to its definitive proxy
statement containing certain historical financial information of the
Company, which should be read in conjunction with the definitive proxy
statement. Stockholders who have questions about the asset sale or need
assistance in submitting their proxy or voting their shares should contact
the Company's proxy solicitor, Morrow & Co., Inc., toll free at
1-800-662-5200.
The Company also announced that it will report its third quarter 2007
financial results on Thursday, November 8, 2007, after the market close.
The Company expects that voting results from the special meeting also will
be reported on that date. The Company will host a live webcast at 4:30 p.m.
EST that day to discuss these results.
The live webcast can be accessed at:
http://phx.corporate-ir.net/phoenix.zhtml?p=irol-
eventDetails&c=100445&eventID=1673091 (Please copy and paste into your
browser) or via the Nabi Biopharmaceuticals website at http://www.nabi.com.
If you do not have Internet access, the U.S./Canada call-in number is
866-202-4683 and the international call-in number is 617-213-8846. The
participant passcode is 65486127. An audio replay will be available for
U.S./Canada callers at 888-286-8010 and for international callers at
617-801- 6888. The replay passcode is 91953104. An archived version of the
webcast will also be available on the Company's website, http://www.nabi.com. Both
the audio replay and the archived webcast will be available through
November 15, 2007. The press release will be available on the company's
website at http://www.nabi.com.
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and, in certain areas, market
products that target serious medical conditions in the areas of hepatitis
and transplants, gram positive bacterial infections and nicotine addiction.
We are a vertically integrated company with sales of antibodies and other
biologics, including Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], a
pipeline of products in various stages of development and a
state-of-the-art manufacturing capability. The company operates through two
strategic business units: Nabi Biologics and Nabi Pharmaceuticals. Nabi
Biologics has responsibility for the company's protein and immunological
products and development pipeline, including Nabi- HB. Nabi Pharmaceuticals
is responsible for the NicVAX(R) (Nicotine Conjugate Vaccine) and
StaphVAX(R) (Staphylococcus aureus Polysaccharide Conjugate Vaccine)
development programs. In September 2007, Nabi announced that it had entered
into a definitive agreement with Biotest AG to sell the Nabi Biologics
strategic business unit to Biotest Pharmaceuticals Corporation, including
Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and other plasma business
assets, including Nabi's state-of-the-art plasma protein production plant,
and nine FDA-certified plasma collection centers across the U.S. The
acquisition also will include certain of Nabi's Corporate Shared Services
group assets and the company's Boca Raton, Florida headquarters and other
facilities, as well as the assumption of certain liabilities. The company
is headquartered in Boca Raton, Florida. For additional information about
Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com/
CONTACT:
Investor Relations, +1-301-770-3099
|
